The Clinical Efficacy and Safety of Tulsi in Humans: A Systematic Review of the Literature.
Tulsi in Hindi or Tulasi in Sanskrit (holy basil in English) is a highly revered culinary and medicinal aromatic herb from the family Lamiaceae that is indigenous to the Indian subcontinent and been used within Ayurvedic medicine more than 3000 years. In the Ayurveda system tulsi is often referred to as an "Elixir of Life" for its healing powers and has been known to treat many different common health conditions. In the Indian Materia Medica tulsi leaf extracts are described for treatment of bronchitis, rheumatism, and pyrexia . Other reported therapeutic uses include treatment of epilepsy, asthma or dyspnea, hiccups, cough, skin and haematological diseases, parasitic infections, neuralgia, headache, wounds, and inflammation  and oral conditions . The juice of the leaves has been applied as a drop for earache , while the tea infusion has been used for treatment of gastric and hepatic disorders . The roots and stems were also traditionally used to treat mosquito and snake bites and for malaria .
Three types of tulsi are commonly described. Ocimum tenuiflorum (or Ocimum sanctum L.) includes 2 botanically and phytochemically distinct cultivars that include Rama or Sri tulsi (green leaves) and Krishna or Shyama tulsi (purplish leaves) [6, 7], while Ocimum gratissimum is a third type of tulsi known as Vana or wild/forest tulsi (dark green leaves) [8, 9]. The different tulsi types exhibit vast diversity in morphology and phytochemical composition including secondary metabolites, yet they can be distinguished from other Ocimum species by the colour of their yellow pollen, high levels of eugenol , and smaller chromosome number . Despite being distinct species with Ocimum tenuiflorum having six times less DNA than Ocimum gratissimum , they are traditionally used in the same way to treat similar ailments . For consistency, this review uses the term tulsi to refer to both Ocimum tenuiflorum or Ocimum gratissimum.
Tulsi has been the subject of numerous scientific studies and its pharmacological and wide range of therapeutic applications are the subject of more than one hundred publications during the last decade alone. Numerous in vitro and animal studies attest to tulsi leaf having potent pharmacological actions that include adaptogenic [12-14], metabolic [15-17], immunomodulatory [18-20], anticancer [21-23], antiinflammatory [24,25], antioxidant [26, 27], hepatoprotective [28, 29], radioprotective [30, 31], antimicrobial [32-35], and antidiabetic effects [36-38] that have been extensively reviewed previously [39-45].
Preclinical studies have demonstrated that tulsi increases swimming survival times in mice and prevents stress-induced ulcers in rats  with antistress effects comparable to antidepressant drugs . Similarly, recent studies report leaf extracts from ethanolic and aqueous tulsi protects rats from stress-induced cardiovascular changes [48, 49]. Studies in animal models have further shown that the leaf extract of tulsi possesses anticonvulsant and anxiolytic activities [50, 51]. Several animal studies conducted over the past fifty years report that ingestion of tulsi leaves improves both glucose and lipid profiles in normal and diabetic-induced animal models [36, 38, 52-58]. Tulsi aqueous leaf extract intramammary infusion has also showed promising effect on improving the immune response in bovine models .
In addition to the extensive literature documenting in vitro and animal research, studies on the use of tulsi as part of a polyherbal formulation in humans has been systematically reviewed . To date, however, there are no systematic reviews on the clinical efficacy and safety of tulsi as a single herbal intervention in humans. The objective of this review was therefore to summarize and critically appraise human clinical trials of tulsi in order to assess the current evidence on tulsi's clinical efficacy and safety.
2. Methods and Materials
2.1. Search Strategies. Relevant clinical studies were identified through searching PubMed, Google Scholar, ScienceDirect, Medline, Embase, Cochrane Library, and Indian Medical databases. The terms in the title or abstract (MeSH and free search terms) alone or in combination searched were "Tulsi", "Tulasi", "Holy Basil", "ocimum sanctum", "Ocimum tenuiflorum", "Ocimum gratissimum", "ocimum", "Albahaca Morada" or combined with "clinical trial", "clinical", or "human".
2.2. Inclusion Criteria. Studies were included if they reported on a human intervention study that involved ingestion of any form of tulsi or holy basil (Ocimum sanctum or Ocimum tenuiflorum or Ocimum gratissimum) and at least one clinical outcome.
2.3. Exclusion Criteria. Studies were excluded if they were reviews, were nonclinical studies, did not involve human subjects, did not report a biological outcome, only involved topical application or only used tulsi at part of a polyherbal formulation, and did not report on the use of tulsi as a single herbal intervention.
2.4. Study Selection. All the titles and abstracts were screened on the basis of the predetermined inclusion and exclusion criteria described above. The full text of each article was reviewed to assess suitability of the study with duplications removed. The search included clinical studies written in the English language and articles from inception until November 2016 in the above-mentioned electronic databases. The references of selected articles were manually searched to identify further relevant studies and, where appropriate, study authors were contacted to request further information.
2.5. Quality Assessment. In order to evaluate the quality of design and implementation of trials, information was collected on the study design, randomization, blinding, and description of participant dropouts and the Jadad scale was used to assess methodological quality .
2.6. Data Extraction. Eligible studies were reviewed with the following data extracted and tabulated: (1) first author name and year of publication; (2) design of the study; (3) Jadad score; (4) study participants (intervention and control groups); (5) extraction method; (6) duration of intervention; (7) tulsi dose and dose form (8) comparator; (9) outcome measure(s) including both primary and secondary, and (10) any adverse event(s).
3.1. Study Description. After screening 1553 studies, a total of 31 articles on tulsi met the inclusion criteria. Four articles were excluded due to being inaccessible and one article reported two independent clinical studies, while one clinical trial was reported in three separate articles. This left a total of 24 independent clinical studies to be reviewed. A flow chart of the systematic search and study selection protocol is presented in Figure 1.
The reviewed studies involved a total of 1111 participants with ages ranging from 10 to 80 years old with eight clinical trials limiting participants to [greater than or equal to] 40 years old [38, 61, 66, 68-70, 72, 75]. Only three clinical trials included 100 or more participants [65, 66, 82]. The study durations ranged from 2 to 13 weeks and tulsi dosage and frequency varied from 300 mg to 3000 mg given as 1-3 times per day as tulsi leaf aqueous extract; 300 mg-1000 mg once or twice per day as tulsi leaf ethanolic extract; 6 g to 14 g per day as the tulsi whole plant aqueous extract; and 10 g fresh tulsi leaf aqueous extract administered as once or four equal doses daily, and as tincture solution 30 drops a day were administered as three equal doses daily.
From the 24 studies identified only eight included a placebo [66, 68, 70, 75-77, 81, 82]. Five of the included trials adopted a two-arm parallel design [62, 63, 65, 67, 80], while four used a cross-over design with one being described in three different papers that reported on two different sets of outcomes [70, 75, 77].
Included studies were classified according to three major clinical domains: metabolic related disorders; immunity; and neurocognitive function (Tables 1,2, and 3). Only two studies described the type of tulsi (Krishna) used while all other papers referred to tulsi as Ocimum sanctum [71, 72] not distinguishing between cultivars. Four studies reported on the use of tulsi alone and along with food, hypoglycemic drug, curry or Neem [63, 67,69,76]. Most studies looked at clinical populations with specific acute or chronic illnesses, such as viral infection, psychological stress, diabetes, or metabolic syndrome, with only three studies reporting on the effects of tulsi in healthy human participants [74, 76, 81].
3.2. Effectiveness and Safety Evaluation. The most common outcome measurements were related to blood glucose levels (8 studies), lipid profile (6 studies), blood pressure (6 studies), immune response (6 studies), and neurocognitive changes (4 studies). Other outcomes included mood (3 studies), fatigue (2 studies), uric acid levels (2 studies), diabetes secondary symptoms (1 study), and sleep (1 study). Fifteen of the 24 included studies reported no adverse events and eight studies did not describe or refer to any adverse events. Only one study that used tulsi leaf extract as 250 mg capsule taken before meals twice daily in 16 obese adults reported the occurrence of occasional nausea.
3.3. Quality Assessment. The studies were classified as either Randomized Clinical Trial Placebo Controlled (RCT-PC 6), Randomized Clinical Trials with no placebo (RCT 7), or Clinical Trials where no information on randomization or control was available (CT 6). Only three out of 24 studies, two of which examined neurocognitive effects [81, 82] and one reported on immunity as well as cardiovascular changes [74, 77], were rated as high quality with Jadad scores of 45 points, with the remaining studies varying in quality with Jadad scores ranging from 0 to 3 points. The score for each included study is presented in Tables 1-3.
3.4. Metabolic Disorders. Seventeen clinical trials reported on metabolic conditions with ten studies reporting on type 2 diabetes or metabolic syndrome with measures of blood glucose, lipids, and blood pressure, yet only one study reported on the clinical symptoms associated with type 2 diabetes such as polydipsia, polyphagia, polyuria, sweating, fatigue, burning feet, itching, and headache . In addition one study reported on obesity  and two studies on uric acid changes in participants with gouty arthritis [38, 65].
Six of the identified trials on metabolic conditions were randomized clinical trials with placebo controls [66, 68, 70, 74,75]. In addition, eight studies were of 2-5 weeks duration [38, 63, 64, 70, 73-75], three were of 6-8 weeks [61, 62, 68], and six were of 12-13 weeks [65-67, 69, 71, 72]. When the duration of the tulsi intervention was increased from 4-5 weeks [38, 70] to 12-13 weeks there was a more dramatic reduction in fasting blood glucose (FBG) and postprandial glucose (PPG) compared to controls [66, 67]. In particular, HbA1c (35.8%) significantly decreased when tulsi was added as adjunct therapy to hypoglycemic medication compared to drug medication alone .
The earliest clinical trial conducted in 1964 with 10 patients with type 2 diabetes reported that over a period of 12 weeks, a 14 g decoction of whole Krishna tulsi plant led to a gradual improvement in fasting blood glucose in 9 out of 10 patients . Three decades later, the first randomized placebo-controlled clinical trial reported daily ingestion of 2.5 g of tulsi leaves led to significant improvements of FBG, PPG, and urine glucose in type 2 diabetes patients after 4 weeks . In addition, Rai et al. reported that 4 weeks of supplementation with tulsi powder significantly lowered blood glucose and glycated proteins, reduced uric acid levels, and improved lipid profiles in participants with type 2 diabetes . In comparable trials with longer durations, FBG and PPG improved by 1.2-2.2 and 1.5-6.0 folds, respectively, while HbA1c improved 1.5 and 3.2 fold after 12-13 weeks [66, 67]. Similarly, lipid profile was improved significantly in MetS and diabetes participants in three clinical trials [38, 66, 68] with a separate clinical trial reporting significant improvement in lipid profile in obese participants  and a further study reporting improved lipid levels in healthy subjects .
A further 12-week study of type 2 diabetes patients reported greater improvement in both blood glucose and HbAc1 levels when 300 mg of tulsi leaf extract was administered along with the antidiabetic drug glibenclamide, compared to drug treatment alone . Similarly, a controlled trial of patients with diabetes found that consumption of 2 g of tulsi powdered leaves, either alone or combined with curry leaves, led to significant improvement in blood sugars after two weeks . In a further 12-week randomized trial in diabetic patients, 2 g of tulsi leaf extract alone or combined with neem leaf extract produced marked reduction in diabetic symptoms with greatest effect noted for the combination .
Six trials reported on the effect of tulsi on individual features of metabolic syndrome [62, 72-75]. Two studies reported significant improvement of blood pressure in hypertensive participants given 30 mL of fresh tulsi leaf juice once daily or 30 mL twice a day for 10 and 12 days, respectively , with a further study reporting normalisation of blood pressure in hypotensive adult females . Yet another study reported improvement in serum lipids with no difference in blood pressure in healthy adults administered 300 mg per day of tulsi leaf ethanolic extract for 4 weeks . A further study reported improved lipid profiles in older adults (60-80 years) with psychosomatic symptoms after administration of 3 g of whole plant tulsi extract twice daily for 12 weeks . A more recent study also reported improvement in lipid profiles, as well as BMI of obese participants administered 250 mg capsules of tulsi leaf extract twice daily for 8 weeks .
3.5. Immunomodulation and Inflammation. Enhanced immune response was reported in five clinical studies [76-80]. A small randomized double-blind, and placebo-controlled trial found increased immune response with increased Natural Killer (NK) and T-helper cells in healthy adult participants compared to placebo volunteers after 4 weeks of 300 mg or ethanolic tulsi leaf extract daily taken before food . Another 2-week controlled randomized study in which young adult volunteers were provided with nutrition bars fortified with 1 g of ethanolic tulsi leaf extract found that compared to control participants, the intervention group had significantly improved VO2 max, less fatigue, reduced Creatine Kinase, and improved immune response to viral infection as indicated by reduced load of human herpesvirus 6 in saliva .
Two clinical trials studied the effect of daily administration of 10 g of an aqueous extract of fresh tulsi leaves in patients with acute viral infections, with a study on patients with acute viral encephalitis reporting increased survival after 4 weeks in the tulsi group compared to a group given dexamethasone and a study on viral hepatitis reporting symptomatic improvement after 2 weeks [79, 80]. A further study of asthmatic patients found that 500 mg of dried tulsi leaves taken three times daily improved vital capacity and provided relief of asthmatic symptoms within 3 days . 3.6. Neurocognitive Effect. The four studies that reported on neurocognitive effects all showed significant improvements in mood and/or cognitive function regardless of age, gender, formulation, dose, or quality of the study [72, 81-83]. Cognition function was assessed in a randomized, placebo-controlled, clinical trial that demonstrated an improvement in cognitive flexibility, short-term memory, and attention in 40 healthy young adults (17-30 years) following treatment with 300 mg daily tulsi for 4 weeks . However, the cognitive effects of tulsi were only significant after the first two weeks compared to the placebo, with no significant difference found in stress levels. This is in contrast to three clinical studies that reported significant reduction in anxiety and stress levels with higher doses of tulsi given over a longer time period [72, 82, 83]. The positive effect of tulsi on mood was demonstrated in three studies, with two studies reporting reductions of 31.6%-39% in overall stress-related symptoms in patients with psychosomatic problems compared to a control group [82, 83].
Despite a long history of traditional use and widespread availability, relatively few human intervention studies have been conducted on the effectiveness of tulsi for clinical conditions and this is the first comprehensive literature review of published human research on the ingestion of tulsi as a single herbal intervention. The studies identified in this review could be classified according to three main clinical domains including metabolic disorders (15 studies), neurocognitive or mood conditions (4 studies), and immunity and infections (5 studies), which are all extremely relevant to the growing world-wide epidemic of lifestyle-related chronic disease. The finding that the reviewed studies reported favourable clinical effects across these domains suggests that tulsi may indeed be an effective adaptogen that has a role in helping to address the psychological, physiological, immunological, and metabolic stresses of modern living.
It is interesting that tulsi has important clinical effects across diverse therapeutic domains, all of which may have inflammation as an underlying factor. The anti-inflammatory effects of tulsi have been previously documented in many in vitro and in vivo studies [43, 85-88], and it is likely that tulsi has multiple bioactive secondary metabolites that act alone or synergistically to inhibit inflammatory pathways. There is also evidence to suggest that tulsi may be useful as an adjunct to pharmacotherapy and nutrition in the treatment of metabolic disorders thereby reducing the need for high doses of drugs, which may have adverse effects. The clinical effects demonstrated in the reviewed studies suggest tulsi may have an important role in addressing other inflammatory disorders and that the Ayurvedic tradition of consuming tulsi on a daily basis may be an effective lifestyle measure to address many modern chronic diseases.
The most commonly used part of the tulsi plant is the leaf (dried or fresh), which is known to contain several bioactive compounds including eugenol, ursolic acid, [beta]-caryophyllene, linalool, and 1,8-cineole [89-91]. Eugenol has been found to be the major bioactive metabolite common to all three tulsi varieties with varying amounts in each cultivar [92, 93] and it has recently been suggested to act via dual cellular mechanisms to lower blood glucose levels. These include competitively preventing the binding of glucose to serum albumin and inhibiting the conversion of complex carbohydrate to glucose . However, while eugenol has been shown to be bioactive, the phytochemical composition of tulsi is very complex and varies depending on different conditions [94-97] and there are many other potential active secondary metabolites such as other phenylpropanoids (methyl eugenol, rosmarinic acid), monoterpenes (ocimene), and sesquiterpenes (germacrene) that could alone or synergistically produce therapeutic benefits .
All reviewed studies reported favourable clinical effects with minimal or no side effects irrespective of dose, formulation, or the age or gender of participants, with only one clinical trial reporting transient mild nausea . As the longest study was only 13 weeks, the failure to report any adverse effects does not preclude the presence of any long term side effects; however, the long traditional history of regular tulsi use suggests any serious long term effects are unlikely and that daily ingestion of tulsi is safe. Furthermore, the results of this review are consistent with previous evidence for the clinical efficacy and safety of tulsi, which includes multiple in vitro and in vivo studies and many human clinical trials in addition to traditional use.
4.1. Limitations and Scope. This review, which comprehensively reviewed all human clinical trials published in English language on ingestion of tulsi as a single herb, has many limitations. While the review included 24 studies and minimized bias by using a systematic and independent search strategy without limiting publication year or study design, we cannot be certain that all studies were located; this is especially due to the fact that almost all studies were conducted in India and published in local journals, some of which are very difficult to access or search. There may also be unpublished studies that report negative outcomes . Furthermore, while the reviewed studies were consistent in reporting positive effects of tulsi in humans, only 7 out of 24 can be considered high quality studies with all but three failing to include a double-blind strategy. Tulsi's therapeutic effects may have therefore been overestimated and while the efficacy of tulsi was reported across a wide range of formulations and doses, many studies also failed to provide details of the cultivar, dosage form, or specific dosage or quality control measures of the tulsi used.
This review suggests that tulsi is an example of the Ayurvedic holistic lifestyle approach to health and appears to provide a vast array of health benefits that offers solutions to many modern day health problems. While the reviewed studies could be classified into three major therapeutic domains, there is insufficient evidence for any specific tulsi formulation to assist in any one condition. More rigorous studies with larger sample sizes and longer durations and standardised formulations are therefore needed before specific recommendations can be made for the treatment of any specific disease. This review further highlights the need to investigate and determine unique signature compounds specific to each of the three tulsi varieties, to not only identify the bioactive metabolites that may synergistically interact, but also shed light on the underlying mechanism of action on metabolic and inflammatory pathways.
Despite the lack of large-scale or long term clinical trials on the effect of tulsi in humans, the findings from 24 human studies published to date suggest that the tulsi is a safe herbal intervention that may assist in normalising glucose, blood pressure and lipid profiles, and dealing with psychological and immunological stress. Furthermore, these studies indicate the daily addition of tulsi to the diet and/or as adjunct to drug therapy can potentially assist in prevention or reduction of various health conditions and warrants further clinical evaluation.
Conflicts of Interest
Professor Marc M. Cohen receives remuneration as a consultant and advisor to Organic India Pty. Ltd., which is a company that manufactures and distributes tulsi products.
This article is the independent work of the authors and Organic India did not have input into the article's content or the decision to publish it.
Negar Jamshidi is a Ph.D. student supported by an RMIT University Scholarship.
 K. Nadkarni and A. Nadkarni, Indian Materia Medica with Ayurvedic, Unani-Tibbi, Siddha, Allopathic, Homeopathic, Naturopathic & Home Remedies, vol. 2, Popular Prakashan Private Ltd, Bombay, India, 1982.
 A. P. Committee, The Ayurvedic Pharmacopoeia of India, Part I, Volume IV, Government of India, Ministry of Health and Family Welfare, Department of Ayurveda, Yoga & Naturopathy, Unani, Siddha and Homoeopathy (AYUSH), New Delhi, India, 1st edition, 2016.
 S. S. Hebbar, V. H. Harsha, V. Shripathi, and G. R. Hegde, "Ethnomedicine of Dharwad district in Karnataka, India--plants used in oral health care," Journal of Ethnopharmacology, vol. 94, no. 2-3, pp. 261-266, 2004.
 H. J. Dadysett, "On the various domestic remedies, with their effects, used by the people of India for certain diseases of the ear," The Lancet, vol. 154, no. 3968, pp. 781-782, 1899.
 R. Chopra and I. Chopra, "Glossary of Indian Medicinal Plants," Council of Scientific & Industrial Research, New Delhi, India, 1992.
 S. K. Kothari, A. K. Bhattacharya, S. Ramesh, S. N. Garg, and S. P. S. Khanuja, "Volatile constituents in oil from different plant parts of methyl eugenol-rich Ocimum tenuiflorum L.f. (syn. O. sanctum L.) grown in South India," Journal of Essential Oil Research, vol. 17, no. 6, pp. 656-658, 2005.
 J. A. Parrotta, Healing Plants of Peninsular India, CABI, Oxfordshire, UK, 2001.
 C. Orwa, A. Mutua, R. Kindt, R. Jamnadass, and A. Simons, Agroforestree Database: A Tree Species Reference and Selection Guide Version 4.0, World Agroforestry Centre ICRAF, Nairobi, Kenya, 2009.
 S. Bhamra, M. Heinrich, C. Howard, M. Johnson, and A. Slater, "DNA authentication of tulsi (Ocimum tenuiflorum) using the nuclear ribosomal internal transcribed spacer (ITS) and the chloroplast intergenic spacer trnH-psbA," Planta Medica, vol. 81, no. 16, PW_20, 2015.
 T. Chowdhury, A. Mandal, S. C. Roy, and D. De Sarker, "Diversity of the genus Ocimum (Lamiaceae) through morpho-molecular (RAPD) and chemical (GC-MS) analysis," Journal of Genetic Engineering and Biotechnology, 2017.
 K. Carovic-Stanko, Z. Liber, V Besendorfer et al., "Genetic relations among basil taxa (Ocimum L.) based on molecular markers, nuclear DNA content, and chromosome number," Plant Systematics and Evolution, vol. 285, no. 1, pp. 13-22, 2010.
 E. Jothie Richard, R. Illuri, B. Bethapudi et al., "Anti-stress activity of Ocimum sanctum: possible effects on hypothalamic-pituitary-adrenal axis," Phytotherapy Research, vol. 30, no. 5, pp. 805-814, 2016.
 M. P. Venu Prasad and F. Khanum, "Antifatigue activity of Ethanolic extract of Ocimum sanctum in rats," Research Journal of Medicinal Plant, vol. 6, no. 1, pp. 37-46, 2012.
 I. Tabassum, Z. N. Siddiqui, and S. J. Rizvi, "Effects of Ocimum sanctum and Camellia sinensis on stress-induced anxiety and depression in male albino Rattus norvegicus," Indian Journal of Pharmacology, vol. 42, no. 5, pp. 283-288, 2010.
 T. Suanarunsawat, G. Anantasomboon, and C. Piewbang, "Antidiabetic and anti-oxidative activity of fixed oil extracted from Ocimum sanctum L. leaves in diabetic rats," Experimental and Therapeutic Medicine, vol. 11, no. 3, pp. 832-840, 2016.
 I. Husain, R. Chander, J. K. Saxena, A. A. Mahdi, and F. Mahdi, "Antidyslipidemic effect of Ocimum sanctum leaf extract in Streptozotocin induced diabetic rats," Indian Journal of Clinical Biochemistry, vol. 30, no. 1, pp. 72-77, 2015.
 T. Raja, R. R. N. Reddy, and M. B. Priyadharshini, "An evaluation of anti-hyperglycemic activity of Ocimum sanctum Linn (leaves) in Wister rats," The Pharma Innovation Journal, vol. 5, no. 1, pp. 1-3, 2016.
 F. J. Sutili, D. M. Gatlin, W. Rossi, B. M. Heinzmann, and B. Baldisserotto, "In vitro effects of plant essential oils on nonspecific immune parameters of red drum, Sciaenops ocellatus L.," Journal of Animal Physiology and Animal Nutrition, vol. 100, no. 6, pp. 1113-1120, 2016.
 D. Panprommin, W. Kaewpunnin, and D. Insee, "Effects of holy basil (Ocimum sanctum) extract on the growth, immune response and disease resistance against Streptococcus agalactiae of Nile tilapia (Oreochromis niloticus)," International Journal of Agriculture and Biology, vol. 18, no. 4, pp. 677-682, 2016.
 S. Godhwani, J. L. Godhwani, and D. S. Was, "Ocimum sanctum- a preliminary study evaluating its immunoregulatory profile in albino rats," Journal of Ethnopharmacology, vol. 24, no. 2-3, pp. 193-198, 1988.
 K. Aruna and V. M. Sivaramakrishnan, "Anticarcinogenic effects of some Indian plant products," Food and Chemical Toxicology, vol. 30, no. 11, pp. 953-956, 1992.
 S. Banerjee, R. Prashar, A. Kumar, and A. R. Rao, "Modulatory influence of alcoholic extract of Ocimum leaves on carcinogen-metabolizing enzyme activities and reduced glutathione levels in mouse," Nutrition and Cancer, vol. 25, no. 2, pp. 205-217, 1996.
 C.-C. Lin, P.-Y. Chao, C.-Y. Shen et al., "Novel target genes responsive to apoptotic activity by ocimum gratissimum in human osteosarcoma cells," American Journal of Chinese Medicine, vol. 42, no. 3, pp. 743-767, 2014.
 S. Godhwani, J. L. Godhwani, and D. S. Vyas, "Ocimum sanctum: an experimental study evaluating its anti-inflammatory, analgesic and antipyretic activity in animals," Journal of Ethnopharmacology, vol. 21, no. 2, pp. 153-163, 1987.
 Y. Tanko, G. M. Magaji, M. Yerima, R. A. Magaji, and A. Mohammed, "Anti-nociceptive and anti-inflammatory activities of aqueous leaves extract of Ocimum Gratissimum (Labiate ) in Rodents," African Journal of Traditional, Complementary and Alternative Medicines, vol. 5, no. 2, pp. 141-146, 2008.
 A. C. Akinmoladun, E. Ibukun, E. Afor, E. Obuotor, and E. Farombi, "Phytochemical constituent and antioxidant activity of extract from the leaves of Ocimum gratissimum," Scientific Research and Essays, vol. 2, no. 5, pp. 163-166, 2007.
 M. A. Kelm, M. G. Nair, G. M. Strasburg, and D. L. DeWitt, "Antioxidant and cyclooxygenase inhibitory phenolic compounds from Ocimum sanctum Linn.," Phytomedicine, vol. 7, no. 1, pp. 7-13, 2000.
 H.-C. Chang, Y.-W. Chiu, Y.-M. Lin et al., "Herbal supplement attenuation of cardiac fibrosis in rats with C[Cl.sub.4]-induced liver cirrhosis," Chinese Journal of Physiology, vol. 57, no. 1, pp. 41-47, 2014.
 R. Chattopadhyay, S. Sarkar, S. Ganguly, C. Medda, and T. Basu, "Hepatoprotective activity of Ocimum sanctum leaf extract against paracetamol induced hepatic damage in rats," Indian Journal of Pharmacology, vol. 24, no. 3, p. 163, 1992.
 P. U. Devi and A. Ganasoundari, "Radioprotective effect of leaf extract of Indian medicinal plant Ocimum sanctum," Indian Journal of Experimental Biology, vol. 33, no. 3, pp. 205-208, 1995.
 P. U. Devi, A. Ganasoundari, B. S. S. Rao, and K. K. Srinivasan, "In vivo radioprotection by ocimum flavonoids: survival of mice," Radiation Research, vol. 151, no. 1, pp. 74-78, 1999.
 M. S. Rahman, M. M. Khan, and M. A. Jamal, "Anti-bacterial evaluation and minimum inhibitory concentration analysis of Oxalis corniculata and Ocimum santum against bacterial pathogens," Biotechnology, vol. 9, no. 4, pp. 533-536, 2010.
 G. Prasad, A. Kumar, and A. K. Singh, "Antimicrobial activity of essential oils of some Ocimum species and clove oil," Fitoterapia, vol. 57, no. 6, pp. 429-432, 1986.
 M. P. Prasad, K. Jayalakshmi, and G. G. Rindhe, "Antibacterial activity of ocimum species and their phytochemical and antioxidant potential," International Journal of Microbiology Research, vol. 4, no. 8, pp. 302-307, 2012.
 C. V. Nakamura, T. Ueda-Nakamura, E. Bando, A. F. Negrao Melo, D. A. Garcia Cortez, and B. P. Dias Filho Filho, "Antibacterial activity of Ocimum gratissimum L. essential oil," Memorias do Instituto Oswaldo Cruz, vol. 94, no. 5, pp. 675-678, 1999.
 R. R. Chattopadhyay, "Hypoglycemic effect of Ocimum sanctum leaf extract in normal and streptozotocin diabetic rats," Indian Journal of Experimental Biology, vol. 31, no. 11, pp. 891-893, 1993.
 J. C. Aguiyi, C. I. Obi, S. S. Gang, and A. C. Igweh, "Hypoglycaemic activity of Ocimum gratissimum in rats," Fitoterapia, vol. 71, no. 4, pp. 444-446, 2000.
 V. Rai, U. Iyer, and U. V. Mani, "Effect of Tulasi (Ocimum sanctum) leaf powder supplementation on blood sugar levels, serum lipids and tissues lipids in diabetic rats," Plant Foods for Human Nutrition, vol. 50, no. 1, pp. 9-16, 1997.
 N. Srinivas, K. Sali, and A. Bajoria, "Therapeutic aspects of Tulsi unraveled: a review," Journal of Indian Academy of Oral Medicine and Radiology, vol. 28, no. 1, article no. 17, 2016.
 M. S. Baliga, S. Rao, M. P. Rai, and P. D'Souza, "Radio protective effects of the Ayurvedic medicinal plant Ocimum sanctum Linn. (Holy Basil): a memoir," Journal of Cancer Research and Therapeutics, vol. 12, no. 1, pp. 20-27, 2016.
 H. R. D. Fonseka, W. M. S. S. K. Kulathunga, A. Peiris, and L. D. A. M. Arawwawala, "A review on the therapeutic potentials of Ocimum sanctum Linn: in the management of diabetes Mellitus (Madhumeha)," Journal of Pharmacognosy and Phytochemistry, vol. 4, no. 3, 2015.
 M. M. Cohen, "Tulsi--Ocimum sanctum: a herb for all reasons," Journal of Ayurveda and Integrative Medicine, vol. 5, no. 4, pp. 251-259, 2014.
 A. A. Kamyab and A. Eshraghian, "Anti-inflammatory, gastrointestinal and hepatoprotective effects of Ocimum sanctum Linn: an ancient remedy with new application," Inflammation and Allergy - Drug Targets, vol. 12, no. 6, pp. 378-384, 2013.
 S. Vishwabhan, V. K. Birendra, and S. Vishal, "A review on ethnomedical uses of Ocimum sanctum (Tulsi)," International Research Journal of Pharmacy, vol. 2, pp. 1-3, 2011.
 P. Pattanayak, P. Behera, D. Das, and S. K. Panda, "Ocimum sanctum Linn. A reservoir plant for therapeutic applications: an overview," Pharmacognosy Reviews, vol. 4, no. 7, pp. 95-105, 2010.
 K. P. Bhargava and N. Singh, "Anti-stress activity of Ocimum sanctum Linn," The Indian journal of medical research, vol. 73, pp. 443-451, 1981.
 M. R. Sakina, P. C. Dandiya, M. E. Hamdard, and A. Hameed, "Preliminary psychopharmacological evaluation of Ocimum sanctum leaf extract," Journal of Ethnopharmacology, vol. 28, no. 2, pp. 143-150, 1990.
 S. Sood, D. Narang, M. K. Thomas, Y. K. Gupta, and S. K. Maulik, "Effect of Ocimum sanctum Linn. on cardiac changes in rats subjected to chronic restraint stress," Journal of Ethnopharmacology, vol. 108, no. 3, pp. 423-427, 2006.
 E. Mitra, D. Ghosh, A. K. Ghosh et al., "Aqueous Tulsi leaf (Ocimum sanctum) extract possesses antioxidant properties and protects against cadmium-induced oxidative stress in rat heart," International Journal of Pharmacy and Pharmaceutical Sciences, vol. 6, no. 1, pp. 500-513, 2014.
 C. O. Okoli, A. C. Ezike, O. C. Agwagah, and P. A. Akah, "Anticonvulsant and anxiolytic evaluation of leaf extracts of Ocimum gratissimum, a culinary herb," Pharmacognosy Research, vol. 2, no. 1, pp. 36-40, 2010.
 F. C. M. Okomolo, J. T. Mbafor, E. N. Bum et al., "Evaluation of the sedative and anticonvulsant properties of three Cameroonian plants," African Journal of Traditional, Complementary and Alternative Medicines, vol. 8, no. 5, pp. 181-190, 2011.
 M. L. Dhar, M. M. Dhar, B. N. Dhawan, B. N. Mehrotra, and C. Ray, "Screening of Indian plants for biological activity: I," Indian Journal of Experimental Biology, vol. 6, no. 4, pp. 232-247, 1968.
 J. Giri, B. Suganthi, and G. Meera, "Effect of Tulasi (Ocimum sanctum) on diabetes mellitus," The Indian Journal of Nutrition and Dietetics, vol. 24, pp. 193-198, 1987.
 A. Sarkar, S. C. Lavania, D. N. Pandey, and M. C. Pant, "Changes in the blood lipid profile after administration of Ocimum sanctum (Tulsi) leaves in the normal albino rabbits," Indian Journal of Physiology and Pharmacology, vol. 38, no. 4, pp. 311-312, 1994.
 S. Gupta, P. K. Mediratta, S. Singh, K. K. Sharma, and R. Shukla, "Antidiabetic, antihypercholesterolaemic and antioxidant effect of Ocimum sanctum (Linn) seed oil," Indian Journal of Experimental Biology, vol. 44, no. 4, pp. 300-304, 2006.
 R. Patil, R. Patil, B. Ahirwar, and D. Ahirwar, "Isolation and characterization of anti-diabetic component (bioactivity--guided fractionation) from Ocimum sanctum L. (Lamiaceae) aerial part," Asian Pacific Journal of Tropical Medicine, vol. 4, no. 4, pp. 278-282, 2011.
 A. Chandra, A. A. Mahdi, R. K. Singh, F. Mahdi, and R. Chander, "Effect of Indian herbal hypoglycemic agents on antioxidant capacity and trace elements content in diabetic rats," Journal of Medicinal Food, vol. 11, no. 3, pp. 506-512, 2008.
 S. S. Reddy, R. Karuna, R. Baskar, and D. Saralakumari, "Prevention of insulin resistance by ingesting aqueous extract of Ocimum sanctum to fructose-fed rats," Hormone and Metabolic Research, vol. 40, no. 1, pp. 44-49, 2008.
 R. Mukherjee, P. K. Dash, and G. C. Ram, "Immunotherapeutic potential of Ocimum sanctum (L) in bovine subclinical mastitis," Research in Veterinary Science, vol. 79, no. 1, pp. 37-43, 2005.
 P. K. Kundu and P. Chatterjee, "Meta-analysis of Diabecon tablets: efficacy and safety," Indian Journal of Clinical Practice, vol. 20, no. 9, p. 653, 2010.
 R. Gandhi, B. Chauhan, and G. Jadeja, "Effect of Ocimum sanctum (Tulsi) powder on hyperglycemic patient," Indian Journal of Applied Research, vol. 6, no. 5, 2016.
 S. Satapathy, N. Das, D. Bandyopadhyay, S. C. Mahapatra, D. S. Sahu, and M. Meda, "Effect of Tulsi (Ocimum sanctum Linn.) supplementation on metabolic parameters and liver enzymes in young overweight and obese subjects," Indian Journal of Clinical Biochemistry, pp. 1-7, 2016.
 P. Venkatesan and R. Sengupta, "Effect of supplementation of Tulsi leaves or curry leaves or combination of both type 2 diabetes," International Journal of Pure & Applied Bioscience (IJPAB), vol. 3, no. 2, pp. 331-337, 2015.
 C. Srinivasa Prasadacharyulu, "Leaves of Ocimum sanctum [LOS]: a potent antidiabetic herbal medicine," International Journal of Innovative Research and Development, vol. 3, no. 4, pp. 277-281, 2014.
 M. Ahmad, A. A. Faraazi, and M. N. Aamir, "The effect of ocimum sanctum and ledum palustre on serum uric acid level in patients suffering from gouty arthritis and hyperuricaemia," Bulletin of the Chemical Society of Ethiopia, vol. 27, no. 3, pp. 469-473, 2013.
 D. K. Devra, K. C. Mathur, R. P. Agrawal, I. Bhadu, S. Goyal, and V. Agarwal, "Effect of tulsi (Ocimum sanctum Linn) on clinical and biochemical parameters of metabolic syndrome," Journal of Natural Remedies, vol. 12, no. 1, pp. 63-67, 2012.
 G. Somasundaram, K. Manimekalai, K. J. Salwe, and J. Pandiamunian, "Evaluation of the antidiabetic effect of Ocimum sanctum in type 2 diabetic patients," International Journal of Life Science and Pharma Research, vol. 5, pp. 75-81, 2012.
 B. Dineshkumar, M. Analava, and M. Manjunatha, "Antidiabetic and hypolipidaemic effects of few common plants extract in type 2 diabetic patients at Bengal," International Journal of Diabetes and Metabolism, vol. 18, no. 2, pp. 59-65, 2010.
 A. Kochhar, N. Sharma, and R. Sachdeva, "Effect of supplementation of Tulsi (Ocimum sanctum) and Neem (Azadirachta indica) leaf powder on diabetic symptoms, anthropometric parameters and blood pressure of non insulin dependent male diabetics," Studies on Ethno-Medicine, vol. 3, no. 1, pp. 5-9, 2009.
 P. Agrawal, V. Rai, and R. B. Singh, "Randomized placebo-controlled, single blind trial of holy basil leaves in patients with noninsulin-dependent diabetes mellitus," International Journal of Clinical Pharmacology and Therapeutics, vol. 34, no. 9, pp. 406-409, 1996.
 N. Luthy, "A study of a possible oral hypoglycemic factor in albahaca morada (Ocimum sanctum L.)," The Ohio Journal of Science, vol. 64, no. 3, pp. 223-224, 1964.
 A. K. Verma, G. P. Dubey, and A. Agrawal, "Biochemical studies on serum Hb, Sugar, Urea and lipid profile under influence of ocimum sanctum L in aged patients," Research Journal of Pharmacy and Technology, vol. 5, no. 6, pp. 791-794, 2012.
 A. Bhargava, L. Gangwar, and H. S. Grewal, "To study the effect of holy basil leaves on low blood pressure (hypotension) women aged 18-30 years," International Conference on Food and Agricultural Sciences, vol. 55, no. 16, pp. 83-86, 2013.
 S. Mondal, B. Mirdha, M. Padhi, and S. Mahapatra, "Dried leaf extract of Tulsi (Ocimum sanctum Linn) reduces cardiovascular disease risk factors: results of a double blinded randomized controlled trial in healthy volunteers," Journal of Preventive Cardiology, vol. 1, no. 4, pp. 177-181, 2012.
 S. Sarvaiya, Studies on hypertension with special reference to hypotensive effect of Ocimum sanctum [Ph.D. thesis], Sardar Patel University, Anand, India, 1986.
 M. Venu Prasad, Antifatigue and Neuroprotective Properties of Selected Species of Ocimum L., University of Mysore, Mysore, India, 2014.
 S. Mondal, S. Varma, V. D. Bamola et al., "Double-blinded randomized controlled trial for immunomodulatory effects of Tulsi (Ocimum sanctum Linn.) leaf extract on healthy volunteers," Journal of Ethnopharmacology, vol. 136, no. 3, pp. 452-456, 2011.
 G. Sharma, "Anti-asthmatic efficacy of Ocimum sanctum," Sachitra Ayurved, vol. 35, pp. 665-668, 1983.
 S. Rajalakshmi, G. Sivanandam, and G. Veluchamy, "Role of Tulsi (Ocimum sanctum Linn.) in the management of Manjal Kamalai (viral hepatitis)," Journal of Research in Ayurveda and Siddha, vol. 9, no. 3-4, pp. 118-123, 1986.
 S. Das, A. Chandra, S. Agarwal, and N. Singh, "Ocimum sanctum (tulsi) in the treatment of viral encephalitis (A preliminary clinical trial)," Antiseptic, vol. 80, pp. 323-327, 1983.
 S. Sampath, S. C. Mahapatra, M. M. Padhi, R. Sharma, and A. Talwar, "Holy basil (Ocimum sanctum Linn.) leaf extract enhances specific cognitive parameters in healthy adult volunteers: a placebo controlled study," Indian Journal of Physiology and Pharmacology, vol. 59, no. 1, pp. 69-77, 2015.
 R. C. Saxena, R. Singh, P. Kumar et al., "Efficacy of an extract of ocimum tenuiflorum (OciBest) in the management of general stress: A Double-blind, Placebo-controlled Study," Evidence-based Complementary and Alternative Medicine, vol. 2012, Article ID 894509, 7 pages, 2012.
 D. Bhattacharyya, T. K. Sur, U. Jana, and P. K. Debnath, "Controlled programmed trial of Ocimum sanctum leaf on generalized anxiety disorders," Nepal Medical College Journal, vol. 10, no. 3, pp. 176-179, 2008.
 A. R. Jadad, R. A. Moore, D. Carroll et al., "Assessing the quality of reports of randomized clinical trials: is blinding necessary?" Controlled Clinical Trials, vol. 17, no. 1, pp. 1-12, 1996.
 U. Malairaman, V. Mehta, A. Sharma, and P. Kailkhura, "Antioxidant, anti-inflammatory, and antidiabetic activity of hydroalcoholic extract of Ocimum sanctum: an in-vitro and in-silico study," Asian Journal of Pharmaceutical and Clinical Research, vol. 9, no. 5, pp. 44-49, 2016.
 S. Kavitha, F. John, and M. Indira, "Amelioration of inflammation by phenolic rich methanolic extract of ocimum sanctum linn. Leaves in isoproterenol induced myocardial infarction," Indian Journal of Experimental Biology, vol. 53, no. 10, pp. 632-640, 2015.
 K. Soni, T. Lawal, S. Wicks, U. Patel, and G. Mahady, "Boswellia serrata and Ocimum sanctum extracts reduce inflammation in an ova-induced asthma model of BALB/c mice," Planta Medica, vol. 81, no. 11, 2015.
 H. L. Kalabharathi, R. N. Suresha, B. Pragathi, V. H. Pushpa, and A. M. Satish, "Anti inflammatory activity of fresh tulsi leaves (Ocimum Sanctum) in albino rats," International Journal of Pharma and Bio Sciences, vol. 2, no. 4, pp. 45-50, 2011.
 B. Bernhardt, K. Szabo, and J. Bernath, "Sources of variability in essential oil composition of Ocimum americanum and Ocimum tenuiflorum," Acta Alimentaria, vol. 44, no. 1, pp. 111-118, 2015.
 P. K. Awasthi and S. C. Dixit, "Chemical Compositions of Ocimum sanctum Shyama and 0cimum sanctum Rama Oils from the Plains of Northern India," Journal of Essential Oil-Bearing Plants, vol. 10, no. 4, pp. 292-296, 2007.
 B. B. Tewari and S. Gomathinayagam, "A critical review on Ocimum tenuflorum, Carica papaya and Syzygium cumini: the medicinal flora of Guyana," Revista Boliviana de Quimica, vol. 31, no. 2, pp. 28-41, 2014.
 A. Anand, R. H. Jayaramaiah, S. D. Beedkar et al., "Comparative functional characterization of eugenol synthase from four different Ocimum species: implications on eugenol accumulation," Biochimica et Biophysica Acta--Proteins and Proteomics, vol. 1864, no. 11, pp. 1539-1547, 2016.
 P. Singh, R. H. Jayaramaiah, S. B. Agawane et al., "Potential dual role of eugenol in inhibiting advanced glycation end products in diabetes: proteomic and mechanistic insights," Scientific Reports, vol. 6, Article ID 18798, 2016.
 M. G. De Vasconcelos Silva, A. A. Craveiro, F. J. Abreu Matos, M. I. L. MacHado, and J. W. Alencar, "Chemical variation during daytime of constituents of the essential oil of Ocimum gratissimum leaves," Fitoterapia, vol. 70, no. 1, pp. 32-34, 1999.
 M. Johnson, "Studies on intra-specific variation in a multipotent medicinal plant Ocimum sanctum Linn. Using isozymes," Asian Pacific Journal ofTropical Biomedicine, vol. 2, no. 1, pp. S21-S26, 2012.
 S. R. Vani, S. F. Cheng, and C. H. Chuah, "Comparative study of volatile compounds from genus Ocimum," American Journal of Applied Sciences, vol. 6, no. 3, pp. 523-528, 2009.
 D. Boonyakiat and P. Boonprasom, "Effect of vacuum cooling and packaging on physico-chemical properties of 'Red' holy basil," Acta Horticulturae, vol. 877, pp. 419-426, 2010.
 P. Singh, R. M. Kalunke, and A. P. Giri, "Towards comprehension of complex chemical evolution and diversification of terpene and phenylpropanoid pathways in Ocimum species," RSC Advances, vol. 5, no. 129, pp. 106886-106904, 2015.
 E. Ernst and M. H. Pittler, "Alternative therapy bias," Nature, vol. 385, no. 6616, 1997.
Negar Jamshidi and Marc M. Cohen
School of Health and Biomedical Sciences, RMIT University, Melbourne, VIC, Australia
Correspondence should be addressed to Marc M. Cohen; email@example.com
Received 21 December 2016; Revised 20 February 2017; Accepted 22 February 2017; Published 16 March 2017
Academic Editor: Daniela Rigano
Caption: Figure 1: Flow chart of systematic search and study selection protocol.
Table 1: Effect of tulsi on metabolic related-disorders in human clinical trials. Clinical Authors Study design Jadad domain (year) score Gandhi et al. Randomized 1 (2016)  controlled clinical trial Satapathy et Randomized parallel 3 al. (2016)  group clinical trial Venkatesan and Clinical trial Sengupta (2015) controlled parallel 0  group Srinivasa Clinical study case Prasadacharyulu report 0 (2014)  Metabolic Ahmad et al. Randomized single- disorders (2013)  blind parallel group 2 Devra et al. Randomized, placebo- 1 (2012)  controlled clinical trial Somasundaram Randomized, et al. (2012) controlled parallel 1  clinical Trial Dineshkumar et Randomized placebo- al. (2010)  controlled clinical 3 trial Kochhar et al. Randomized, (2009)  clinical trial 1 Rai et al. Clinical trial 1 (1997)  controlled group Agrawal et al. Randomized, single- 1 (1996)  blind, Placebo- controlled cross- over Luthy (1964) Clinical trial 1  Verma et al. Clinical trial 0 (2012)  Bhargava et al., Clinical study open 1 (2013)  label Randomized, double- Mondai et al. blind, placebo- 5 (2012)  controlled cross- over leaves Sarvaiya (1986) Randomized placebo  controlled cross- 1 over Sarvaiya (1986) Randomized placebo-  controlled 1 Clinical Participants ** Tulsi Intervention domain (age range) extract Duration * 40 male adults Tulsi leaves caps 6.5 weeks T2DM (45-55 years) 30 adults Obesity Tulasi1 leaves caps 8 weeks (17-30 years) 30 adults T2DM Tulsi powder leaves 2 weeks 3 adults T2DM Fresh tulsi leaves 5 weeks Metabolic 200 adults Tincture(2) from disorders Gouty Arthritis tulsi 12 weeks 100 adults MetS Aqueous tulsi Leaves 12 weeks (>40 years) 60 adults Tulsi leaves + T2DM glibenclamide 13 weeks (30-65 years) drug 40 adults T2DM (45-55 years) Aqueous tulsi leaves 8 weeks 90 male adults Powder 12 weeks T2DM/MetS tulsi leaves (40-60 years) 27 adults T2DM/MeS Tulsi powder leaves 4 weeks (45-65 years) 40 adults T2DM Tulsi powder leaves 5 weeks (41-65 years) (+5-day wash out) 10 adults T2DM Whole plant 12 weeks decoction 5 adults Powder whole plant psychosomatic tulsi Fresh juice 15 12 weeks (60-80 years) tulsi leaves 50 Female adults hypotensive 4 weeks (18-30 years) 22 healthy adults Ethanolic 4 weeks (22-37 years) tulsi (+3-week wash-out) 20 adults, Fresh Juice 75% 10 days hypertension tulsi (+5-day (45-64 years) wash-out) 16 adults, Fresh Juice 75% hypertension tulsi 12 days (45-64 years) Clinical Intervention Comparator domain Dosage 3 g/day before meal Not disclosed 250mg/day 2x daily Parallel group no before meal intervention Curry leaves tulsi + 2g/day curry fresh leaves (3) 3x None daily Metabolic 10 drops 3 times/day Tincture disorders wild rosemary 10 drops x 3/day 5 mL/x2 day before Not disclosed meals 300 mg/day tulsi 5 mg/day + 5 mg glibenclamide Glibenclamide 500 g/day Water 2g/day Neem neem + tulsi lg/day in morning None before meal 2.5g/day in morning Spinach powder before meal leaves 2.5 g/day 14 g/day None 3 g x 2/day None Juice x 2/day None 300 mg/day 300 mg/day before food sucrose Green colored 30 mL/day water 30 mL/day before meal 30 mL Green-colored 2 times a day before water 30 mL x 2/day before meals Clinical Outcome Adverse domain measure(s) events (s) Significant! Not reported postprandial glucose & fasting blood glucose Improved BMI, lipid Mild nausea profile (except TC), TG & IR Significant[down Not reported arrow] post- prandial glucose & fasting blood Considerable decrease in blood None glucose reaching near normal levels Metabolic Significant disorders reduction in serum Not reported uric acid Improved lipid Not reported profile, fasting blood glucose, and BP Significant [down arrow] [fasting blood None & postprandial glucose reduced HBA1c Significant improvement in lipid None profile Improved T2DM Not symptoms: [down reported arrow] polydipsia, [down arrow] polyphagia, & BP Improved lipid Not reported profile, blood glucose, glycated proteins (HbA1c) & UA Significant [down None arrow] fasting blood glucose, post- prandial glucose and urine glucose Reduced blood None glucose in 9 T2DM adults Significant improvement in lipid None profile Significant changes, Not reported in Blood pressure Reduction in lipid None profile, in 6 participants Significant [down None arrow] blood pressure Significant [down arrow] blood None pressure (lowered by 25%) BMI = body mass index measured by weight (kg)/height ([m.sup.2]); BP = blood pressure; HbA1C = glycosylated haemoglobin; IR = insulin resistance; MetS = metabolic syndrome; T2DM = type 2 diabetes mellitus; TC = total cholesterol, TG = triglycerides; UA = uric acid. * Intervention duration is the time the intervention was administered excluding any washout periods. ** Participants who completed the study are listed excluding any drop-outs. (1) Tulasi Tablets are product of Himalaya Herbal Healthcare Pharmaceutical Company in India. (2) Tincture is a product of BM private limited. (3) The quantity of tulsi fresh leaves was not specified; "handful" of leaves was given to each patient. Table 2: Effect of tulsi on immune system and viral infections in human clinical trials. Clinical Authors Study design Jadad domain (year) score Venu Prasad Randomized, placebo- 3 (2014)  controlled clinical trial Immunomodulation Mondaf et al. Randomized, double- 5 (2011)  blind, placebo- controlled cross- over Sharma (1983) Open clinical trial 1  Viral infections Rajalakshmi et Clinical trial 0 al. (1986)  Das et al. Randomized clinical 1 (1983)  trial parallel- controlled Clinical Participants ** Tulsi domain (age range) extract 30 healthy adults Ethanolic (18-30 years) tulsi leaves in Bar * Immunomodulation 22 healthy adults Ethanolic (22-37 years) tulsi leaves 20 adults, asthma Aqueous tulsi leaves tablets Viral infections 20 cases, viral Aqueous extract hepatitis (10-60 fresh tulsi leaves years) 14 adults, viral Aqueous extract encephalitis fresh tulsi leaves Clinical Intervention domain Duration * Dosage 2 weeks 1 bar x 2/day (1000 mg tulsi) Immunomodulation 4 weeks (+3 weeks 300 mg/day wash out) 1 week 500 mg x 3/day Viral infections 2 weeks for mild 10 g daily cases 3 weeks for Severe cases 4 weeks 2.5 g 4 times/day Clinical Comparator Outcome domain measure(s) Not described [up arrow] physical "control bar" performance, [down arrow] fatigue and CK levels less increase in lactic acid Immunomodulation Cellulose 300 mg/day Increased cytokine level, interferon- [gamma], & interleukin-4 None Relief within 3 days, improved vital capacity Viral infections None Symptoms all improved within 2 weeks 12 mg/day Increased survival dexamethasone rate compared to treated group steroid Clinical Adverse domain events (s) None Immunomodulation None None Viral infections None Not reported CK = creatine kinase; TPE = tropical pulmonary eosinophilia. * Intervention duration included wash-out periods where applicable until study was completed. ** Participants include both control and intervention groups completing the study and excluded any drop-outs. ([dagger]) Same results as previously published (Mondai et al., 2010). ([double dagger]) Tulsi enriched bar: each 25 g bar contained oats, resin, peanuts, skimmed milk powder, sugar, and honey and 0.5% ethanolic tulsi. Table 3: Therapeutic effects of tulsi on cognitive function, mood, and stress in human clinical trials. Clinical Authors Study design Jadad domain (year) score Randomized, Sampath et al. double-blind, 5 (2015)  placebo controlled clinical trial Saxena et al. Randomized, (2012)  double-blind, 4 Neurocognition placebo-controlled Verma ([double dagger]) Clinical trial et al. (2012)  0 Bhattacharyya et al. Clinical trial (2008)  1 Clinical Participants ** Tulsi Intervention domain (age range) extract Duration * 40 healthy adults Ethanolic tulsi (18-30 years) leaves capsules 4 weeks 150 adults, OCIBEST1' stress whole plant 6 weeks Neurocognition (18-65 years) capsules 24 adults, powder psychosomatic whole plant 12 weeks (60-80 years) tulsi 35 adults Ethanolic with GAD tulsi leaves 8 weeks (18-60 years) capsules Clinical Intervention Comparator Outcome domain Dosage measure(s) Cognitive 300 mg/day Cellulose flexibility, before meals capsules attention, Improved working memory only after day 15 400 mg Cellulose Reduction in stress 3 times/day capsules related symptoms: Neurocognition after meals fatigue, sleep and sexual problems Reduced anxiety 3 g x 2/day None significantly lowered biological age score 500 mg Self-reported 2x daily None questionnaire, 1 after meals anxiety, stress, & depression Clinical Adverse domain events (s) None None Neurocognition None None GAD = generalized anxiety disorder. * Intervention duration is the time the intervention was administered excluding any washout periods. ** Participants include both control and intervention groups completing the study and excluded any drop-outs. ([dagger]) OCIBEST is product of natural remedies and contains tulsi whole plant. ([double dagger]) Authors also reported findings from glucose and lipid profile for 5 of the participants and found lipid profile significantly improved.